Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1.
Pharmacol Biochem Behav
; 84(2): 252-8, 2006 Jun.
Article
em En
| MEDLINE
| ID: mdl-16782179
ABSTRACT
[Dmt1]Endomorphin-1 is a novel analogue of the potent mu-opioid agonist endomorphin-1. Given the physiological role of endomorphin-1 in vivo, this compound was investigated to determine if the antinociception occurred through systemic, supraspinal or in a combination of both neuronal pathways. This compound exhibited a potent dose-dependent effect intracerebroventricularly in both spinal and supraspinal regions, and was blocked by opioid antagonist naloxone, which verified the involvement of opioid receptors. Specific opioid antagonists characterized the apparent receptor type beta-funaltrexamine (mu1/mu2-irreversible antagonist) equally inhibited spinal- and central-mediated antinociception; on the other hand, naloxonazine (mu1-subtype) was ineffective in both neural pathways and naltrindole (delta-selective antagonist) partially (26%), though not significantly, blocked only the spinal-mediated antinociception. Therefore, spinal antinociception was primarily triggered by mu2-subtypes without involvement of mu1-opioid receptors; however, although a slight enhancement of antinociception by delta-receptors cannot be completely ruled out since functional bioactivity indicated mixed mu-agonism/delta-antagonism. In terms of the CNS action, [Dmt1]endomorphin-1 appears to act through mu2-opioid receptor subtypes.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Oligopeptídeos
/
Receptores Opioides delta
/
Receptores Opioides mu
/
Analgesia
Limite:
Animals
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article